Disease/Infection News

RSS

Avian influenza A H3N8 virus poses threat to humans

A study led by St. Jude Children's Research Hospital scientists found the avian influenza A H3N8 virus that killed harbor seals along the New England coast can spread through respiratory droplets and poses a threat to humans.

5 Sep 2014

World leaders failing to address worst ever Ebola outbreak

International leaders are failing to adequately respond to what is the worst Ebola epidemic in history, announced Doctors Without Borders/Médecins Sans Frontières (MSF) at a United Nations briefing held on Tuesday.

4 Sep 2014

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

4 Sep 2014

Leading experts propose new treatment guidelines for chronic Lyme disease

Current treatments for Lyme disease, particularly chronic forms of the disease, are inadequate, according to a new treatment guideline written by a group of leading experts.

4 Sep 2014

Case Western Reserve scientists discover leaky gut as source of non-AIDS complications

Human immunodeficiency virus (HIV) infection is no longer a fatal condition, thanks to newer medications inhibiting the retrovirus, but a puzzling phenomenon has surfaced among these patients — non-AIDS complications. Scientists at Case Western Reserve University School of Medicine have resolved the mystery with their discovery of the leaky gut as the offender.

4 Sep 2014

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221.

4 Sep 2014

Findings may help develop biomarkers to identify HIV patients at risk of dementia

Since the introduction of the combination anti-retroviral therapy (cART) in the mid-90s, the life expectancy of HIV patients has significantly improved. As a result, long-term complications are becoming more relevant: almost every second HIV patient is affected by neurocognitive disorders, which can lead to dementia.

4 Sep 2014

New antibody in HIV-infected person binds to virus

An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit.

4 Sep 2014

Football players are found to be carriers of sickle cell trait later in life

From 2000 to 2014, nine collegiate football players unexpectedly collapsed and died during training. The cause? Muscle breakdown leading to organ failure.

4 Sep 2014

3 billion people worldwide at risk of early death due to household air pollution

Household air pollution, caused by the use of plant-based or coal fuel for cooking, heating, and lighting, is putting nearly three billion people worldwide at risk of ill health and early death, according to a new Commission, published in The Lancet Respiratory Medicine journal.

4 Sep 2014

Nosopharm reports findings on Odilorhabdins that has potential to combat antibiotic resistance

Nosopharm, a specialist in the research and development of new anti-infective drugs, announces today its in vitro and in vivo findings for a novel antibacterial class, Odilorhabdins, which has the potential to combat antibiotic resistance.

4 Sep 2014

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.

4 Sep 2014

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study.

4 Sep 2014

Legatum Foundation donates $150,000 to Ebola Crisis Fund

The Legatum Foundation, the development arm of the Legatum Group, today announced a donation of $150,000 to the Ebola Crisis Fund, a fund established to help prevent the spread of the deadly Ebola virus in West Africa.

3 Sep 2014

New regulatory component in infectious bacterium helps explain ability to survive in human body

The discovery of a new regulatory component in an infectious bacterium could aid efforts to explain its ability to survive in the human body, report microbiologists at The University of Texas Health Science Center at Houston (UTHealth) and University of Maryland, College Park, in the journal Science.

3 Sep 2014

Disease/Infection News

Avian influenza A H3N8 virus poses threat to humans

World leaders failing to address worst ever Ebola outbreak

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Leading experts propose new treatment guidelines for chronic Lyme disease

Case Western Reserve scientists discover leaky gut as source of non-AIDS complications

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Findings may help develop biomarkers to identify HIV patients at risk of dementia

New antibody in HIV-infected person binds to virus

Football players are found to be carriers of sickle cell trait later in life

3 billion people worldwide at risk of early death due to household air pollution

Nosopharm reports findings on Odilorhabdins that has potential to combat antibiotic resistance

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

Legatum Foundation donates $150,000 to Ebola Crisis Fund

New regulatory component in infectious bacterium helps explain ability to survive in human body

Scientists make important breakthrough in fight against debilitating autoimmune diseases

Researchers discover pattern of infection of bacterium responsible for causing severe lung infections

Biochemists discover proteins that could lead to better treatments for life-threatening infections

Study suggests phages are sophisticated bacterial predators and can prevent infections

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News